These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22241164)

  • 21. P50 sensory gating, cognitive deficits and depressive symptoms in first-episode antipsychotics-naïve schizophrenia.
    Li S; Yu B; Wang D; Xia L; Wang L; Chen D; Xiu M; Zhang XY
    J Affect Disord; 2023 Mar; 324():153-161. PubMed ID: 36587903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abnormal auditory sensory gating-out in first-episode and never-medicated paranoid schizophrenia patients: an fMRI study.
    Ji B; Mei W; Zhang JX; Jing J; Wu Q; Zhuo Y; Xiao Z
    Exp Brain Res; 2013 Aug; 229(2):139-47. PubMed ID: 23820976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine.
    Rasmussen H; Ebdrup BH; Erritzoe D; Aggernaes B; Oranje B; Kalbitzer J; Pinborg LH; Baaré WF; Svarer C; Lublin H; Knudsen GM; Glenthoj B
    Psychopharmacology (Berl); 2011 Feb; 213(2-3):583-92. PubMed ID: 20614105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P50 inhibition defects with psychopathology and cognitive impairment in patients with first-episode drug naïve schizophrenia.
    Xia L; Wang D; Wei G; Wang J; Zhou H; Xu H; Tian Y; Dai Q; Xiu M; Chen D; Wang L; Zhang X
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Apr; 107():110246. PubMed ID: 33453321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Various effects of antipsychotics on P50 sensory gating in Chinese schizophrenia patients: a meta-analysis.
    Su L; Cai Y; Wang L; Shi S
    Psychiatr Danub; 2012 Mar; 24(1):44-50. PubMed ID: 22447085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of acute exogenous melatonin on P50 suppression in healthy male volunteers stratified for low and high gating levels.
    Ucar E; Lehtinen EK; Glenthøj BY; Oranje B
    J Psychopharmacol; 2012 Aug; 26(8):1113-8. PubMed ID: 22331175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.
    Csomor PA; Preller KH; Geyer MA; Studerus E; Huber T; Vollenweider FX
    Neuropsychopharmacology; 2014 Sep; 39(10):2485-96. PubMed ID: 24801767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensory gating in adult with attention-deficit/hyperactivity disorder: Event-evoked potential and perceptual experience reports comparisons with schizophrenia.
    Micoulaud-Franchi JA; Vaillant F; Lopez R; Peri P; Baillif A; Brandejsky L; Steffen ML; Boyer L; Richieri R; Cermolacce M; Bioulac S; Aramaki M; Philip P; Lancon C; Vion-Dury J
    Biol Psychol; 2015 Apr; 107():16-23. PubMed ID: 25766264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clonidine normalizes levels of P50 gating in patients with schizophrenia on stable medication.
    Oranje B; Glenthøj BY
    Schizophr Bull; 2014 Sep; 40(5):1022-9. PubMed ID: 24106334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The follow-up study on P50 auditory sensory gating in naïve schizophrenia].
    Wang HX; Zhang MD; Wang ZC; Chen XS; Lou FY; Liang JH; Chen C
    Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(9):601-5. PubMed ID: 20450782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-analysis of auditory P50 sensory gating in schizophrenia and bipolar disorder.
    Atagun MI; Drukker M; Hall MH; Altun IK; Tatli SZ; Guloksuz S; van Os J; van Amelsvoort T
    Psychiatry Res Neuroimaging; 2020 Jun; 300():111078. PubMed ID: 32361172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Olanzapine effects on auditory sensory gating in schizophrenia.
    Arango C; Summerfelt A; Buchanan RW
    Am J Psychiatry; 2003 Nov; 160(11):2066-8. PubMed ID: 14594761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of cognitive and P50 suppression deficits in chronic patients with schizophrenia.
    Xia L; Wang D; Wang J; Xu H; Huo L; Tian Y; Dai Q; Wei S; Wang W; Zhang G; Du X; Jia Q; Zhu X; Wang L; Tang W; Zhang XY
    Clin Neurophysiol; 2020 Mar; 131(3):725-733. PubMed ID: 32000073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The adenosine antagonist theophylline impairs p50 auditory sensory gating in normal subjects.
    Ghisolfi ES; Prokopiuk AS; Becker J; Ehlers JA; Belmonte-de-Abreu P; Souza DO; Lara DR
    Neuropsychopharmacology; 2002 Oct; 27(4):629-37. PubMed ID: 12377399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spectral decomposition of P50 suppression in schizophrenia during concurrent visual processing.
    Moran ZD; Williams TJ; Bachman P; Nuechterlein KH; Subotnik KL; Yee CM
    Schizophr Res; 2012 Sep; 140(1-3):237-42. PubMed ID: 22840844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of increased serotonergic activity on human sensory gating and its neural generators.
    Jensen KS; Oranje B; Wienberg M; Glenthøj BY
    Psychopharmacology (Berl); 2008 Mar; 196(4):631-41. PubMed ID: 18000656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential effects of nicotine on P50 amplitude, its gating, and their neural sources in low and high suppressors.
    Knott VJ; Fisher DJ; Millar AM
    Neuroscience; 2010 Oct; 170(3):816-26. PubMed ID: 20643194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct neural generators of sensory gating in schizophrenia.
    Williams TJ; Nuechterlein KH; Subotnik KL; Yee CM
    Psychophysiology; 2011 Apr; 48(4):470-8. PubMed ID: 20735757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker.
    Hashimoto K
    Curr Pharm Des; 2015; 21(26):3797-806. PubMed ID: 26044974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels.
    Csomor PA; Stadler RR; Feldon J; Yee BK; Geyer MA; Vollenweider FX
    Neuropsychopharmacology; 2008 Feb; 33(3):497-512. PubMed ID: 17460616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.